Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum

Dow Jones

2025/03/05

By Adriano Marchese

Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter.

Shares traded 9.8% higher at $11.03.

The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet.

Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents.

Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025.

"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company," Bolno said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 04, 2025 12:33 ET (17:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517604286"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517604286\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517604286?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 01:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517604286","market":"fut","top_or_hot":-1,"title":"Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n</p>\n<p>\n  Shares traded 9.8% higher at $11.03. \n</p>\n<p>\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n</p>\n<p>\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n</p>\n<p>\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n</p>\n<p>\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 12:33 ET (17:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences Shares Up on 4Q Revenue Beat, 2025 Momentum\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-05 01:33</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n</p>\n<p>\n  Shares traded 9.8% higher at $11.03. \n</p>\n<p>\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n</p>\n<p>\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n</p>\n<p>\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n</p>\n<p>\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 04, 2025 12:33 ET (17:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2517604286","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517604286","pubTimestamp":1741109580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter.The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet.Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents.Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025.\"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"Wave Life Sciences股价因第四季度收入超出预期和2025年势头而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares of Wave Life Sciences rose Tuesday after reporting that its revenue more than doubled, topping expectations, and a profit for the fourth quarter. \n\n\n  Shares traded 9.8% higher at $11.03. \n\n\n  The RNA-focused biotechnology company reported revenue of $83.7 million for the fourth quarter compared with $29.1 million in the prior-year period, and topping analyst expectations of $28.7 million, according to FactSet. \n\n\n  Net income was $29.3 million, compared with a loss of $16.3 million. On a per-share basis, this was 17 cents profit, up from a loss of 15 cents. \n\n\n  Chief Executive Paul Bolno said 2024 was an exceptional year for the company and that the positive momentum has continued so far into 2025. \n\n\n  \"With both our progress in the clinic and in advancing a broad pipeline targeting high-impact biology, we are building a leading RNA medicines company,\" Bolno said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 12:33 ET (17:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}